(19)
(11) EP 3 131 897 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
03.08.2022 Bulletin 2022/31

(45) Mention of the grant of the patent:
15.06.2022 Bulletin 2022/24

(21) Application number: 15780578.9

(22) Date of filing: 10.04.2015
(51) International Patent Classification (IPC): 
C07D 413/14(2006.01)
C07D 207/02(2006.01)
 C07D 261/20(2006.01)
(52) Cooperative Patent Classification (CPC):
C07D 413/04; C07D 417/14; C07D 498/04; C07D 519/00; A61K 31/423; A61K 31/428; A61K 31/437; A61K 31/4439; A61K 31/497; A61K 31/501; A61K 31/506; A61K 31/52; C07D 471/04; C07D 413/14
(86) International application number:
PCT/US2015/025229
(87) International publication number:
WO 2015/160636 (22.10.2015 Gazette 2015/42)

(54)

FACTOR IXA INHIBITORS

FAKTOR-IXA-HEMMER

INHIBITEURS DU FACTEUR IXA

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 16.04.2014 US 201461980363 P

(43) Date of publication of application:
22.02.2017 Bulletin 2017/08

(73) Proprietors:
  • Merck Sharp & Dohme LLC
    Rahway, New Jersey 07065-0907 (US)
  • Mochida Pharmaceutical Co., Ltd.
    Tokyo 160-8515 (JP)

(72) Inventors:
  • SAKURADA, Isao
    Tokyo 160-8515 (JP)
  • HIRABAYASHI, Tomokazu
    Tokyo 160-8515 (JP)
  • MAEDA, Yoshitaka
    Tokyo 160-8515 (JP)
  • NAGASUE, Hiroshi
    Tokyo 160-8515 (JP)
  • MIZUNO, Takashi
    Tokyo 160-8515 (JP)
  • XU, Jiayi
    Rahway New Jersey 07065-0907 (US)
  • ZHANG, Ting
    Rahway New Jersey 07065-0907 (US)
  • SMITH, Cameron
    Lawrenceville New Jersey 08648-2679 (US)
  • PARKER, Dann
    Rahway New Jersey 07065-0907 (US)

(74) Representative: Hussain, Deeba et al
Merck Sharp & Dohme Corp. 120 Moorgate
London, EC2M 6UR
London, EC2M 6UR (GB)


(56) References cited: : 
WO-A1-2013/056060
US-A1- 2006 247 238
 US-A- 5 254 556
US-B2- 7 235 575
   
  • DATABASE PUBCHEM [Online] 05 December 2007 XP055231093 Database accession no. 20718874
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).